

UnitedHealth Plunges, Lilly Gains on Weight-Loss Pill, Trump Slams Powell 4/17/25
Apr 17, 2025
UnitedHealth faces a significant stock plunge after disappointing earnings and guidance revisions, impacting the Dow negatively. In contrast, Eli Lilly celebrates a surge thanks to successful trial results for its experimental weight-loss pill. The discussion heats up as President Trump criticizes Jerome Powell, urging for swift changes in leadership at the Federal Reserve. Also, insights into Nvidia's operations in China and a positive earnings report from Taiwan Semiconductor highlight tech trends amidst market volatility.
AI Snips
Chapters
Books
Transcript
Episode notes
UnitedHealth's Rare Earnings Miss
- UnitedHealth missed earnings due to underestimating medical care costs across all divisions.
- This rare error disrupted the market and pulled down the Dow significantly on the news.
Lilly's Breakthrough Weight-Loss Pill
- Eli Lilly's experimental obesity pill shows promise with around 8% weight loss in 40 weeks.
- A pill alternative is crucial since most people reject injectable weight loss treatments.
Trump Slams Powell Amid Rate Debate
- President Trump disparaged Fed Chair Jerome Powell on social media over interest rate policy.
- Powell's historical perspective emphasizes avoiding tariff-induced economic harm, despite presidential criticism.